Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant hIL-31. Human IL-31 specific antibody was purified by affinity chromatography and then biotinylated.
IL31
Reaktivität: Human
ELISA
Wirt: Maus
Monoclonal
SB118b
Biotin
Applikationshinweise
ELISA: Direct: To detect hIL-31 by direct ELISA (using 100 μ,L/well antibody solution) a concentration of 0.25 - 1.0 μ,g/mL of this antibody is required. This biotinylated polyclonal antibody, in conjunction with compatible secondary reagents, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hIL-31.
Sandwich To detect hIL-31 by sandwich ELISA (using 100 μ,L/well antibody solution) a concentration of 0.25 - 1.0 μ,g/mL of this antibody is required. This biotinylated polyclonal antibody, in conjunction with our polyclonal Anti-Human IL-31 as a capture antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hIL-31.
Western Blot: To detect hIL-31 by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 μ,g/mL. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIL-31 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Lagerung
-20 °C
Informationen zur Lagerung
IL-31 antibody is stable for at least 2 years from date of receipt at -20°C. The reconstituted antibody is stable for at least two weeks at 2-8°C. Frozen aliquots are stable for at least 6 months when stored at -20°C. Avoid repeated freeze-thaw cycles.
Target
IL-31 (IL31)
(Interleukin 31 (IL31))
Andere Bezeichnung
IL-31
Hintergrund
Interleukin 31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia and skin lesions, and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development.